Bristol Myers' Breyanzi Sales Skyrocket 125%, Boosting Portfolio Amid Generic Competition

Bristol Myers' (BMY) CAR T cell therapy Breyanzi sales surged 125% to $344 million in Q2, driven by strong demand across all indications and improved manufacturing success rate. BMY expects strong growth in H2 2025, but faces competition from Gilead Sciences' Yescarta for approved indications. BMY is banking on its immuno-oncology portfolio, including Reblozyl and Camzyos, to stabilize its revenue base as legacy drugs face generic competition.

Bristol Myers Squibb (BMY) reported a significant surge in sales for its CAR T cell therapy, Breyanzi, in the second quarter of 2025. The company's sales for Breyanzi surged 125% to $344 million, driven by strong demand across all indications and improved manufacturing success rates [1].

The company's CAR T cell therapy, Breyanzi, has been accepted by the FDA for Priority Review as a potential treatment for relapsed or refractory marginal zone lymphoma (MZL) in adults who have received ≥2 prior lines of systemic therapy. If approved, Breyanzi could become the first and only CAR T cell therapy for MZL, offering a much-needed option for patients who often face multiple relapses over the course of their disease [1].

Despite the surge in sales, Bristol Myers Squibb faces competition from Gilead Sciences' Yescarta for approved indications. Gilead's Yescarta sales were down 5% in Q2 2025, but the company remains optimistic about the rest of the CAR T-cell-heavy pipeline under its Kite Pharma subsidiary [2].

Bristol Myers Squibb is banking on its immuno-oncology portfolio, including Reblozyl and Camzyos, to stabilize its revenue base as legacy drugs face generic competition. The company's overall sales in the oncology segment inched up 1% to $849 million in Q2 2025, driven by strong sales of Trop-2-directed antibody-drug conjugate Trodelvy [2].

Bristol Myers Squibb expects strong growth in H2 2025, with a lifted revenue guidance for the full year to $47 billion at the midpoint from $46.3 billion. The company's operating margin improved to 18.5% year on year [3].

References:

[1] https://oncodaily.com/voices/yan-leyfman-345607
[2] https://www.precisionmedicineonline.com/precision-oncology/gileads-optimistic-relaxed-car-t-safety-monitoring-could-help-sluggish-yescarta
[3] https://ca.finance.yahoo.com/news/bristol-myers-squibb-q2-earnings-042559719.html